Innovotech Inc. Reports Financial Results for 2025

Edmonton, Alberta — March 31, 2026 — Leads & Copy —

Innovotech Inc. (TSXV: IOT) (“Innovotech” or the “Company”), a life sciences services and technology company specializing in applied microbiology and analytical chemistry within regulated healthcare markets, has released its financial results for the three and twelve months ending December 31, 2025.

The company’s audited consolidated financial statements and Management’s Discussion and Analysis (“MD&A”) have been filed on SEDAR+.

Innovotech reported annual revenue totaling $4,534,852 in 2025, more than double the $2,194,471 reported in 2024. According to the company, revenue growth was driven primarily by a full‑year contribution from Keystone Labs Inc., as well as steady demand across antimicrobial contract research, analytical chemistry, GMP microbial testing, and stability testing services.

Gross profit for the year was $2,397,039, representing a gross margin of 52.9%.

Innovotech reported a net income of $88,634 for the year.

In the fourth quarter of 2025, Innovotech generated revenue of $1,124,648, consistent with the company’s experience throughout the year.

At year‑end, Innovotech maintained a strong cash position and reported growth in shareholders’ equity. Management believes the Company is well positioned to support continued organic growth, strategic initiatives, and future investment in capacity and capabilities.

The company says it is a recognized leader in biofilm science and antimicrobial testing, providing advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. Innovotech combines scientific expertise with proprietary methodologies and products, including its MBEC Assay® platform for high‑throughput antimicrobial and antibiotic testing.

Operating through ISO‑certified and GMP‑accredited laboratories, Innovotech supports clients across sectors and geographies, delivering decision‑enabling data aligned with regulatory expectations such as those of the U.S. Food and Drug Administration and Health Canada.

Source: Innovotech Inc.